BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (November 2015)
25 slides from BioSpecifics Technologies's investor presentation, Nov 10, 2015
Slide 1: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE ttt. ; BioSpecifics November 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding
Slide 3: Company Overview
Company Overview BioSpecifics (Nasdaq: BSTC) is a profitable biopharma company. Originator of collagenase based-therapies. Receives revenues from XIAFLEX® (collagenase clostridium lhistolyticum or CCH) milestones, royalties on net sales, mark-up on COGS and sublicense income by partner Endo. Future
Slide 4: Unlocking Vast Potential of CCH
Unlocking Vast Potential of CCH First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive clinical results in 12 indications: Dupuytren’s contracture’ Adhesive capsulitist Scarred tendons P
Slide 5: XIAFLEX for Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture First, Effective Non-Surgical Treatment Option Collagen cord in hand causing one or more fingers to contract toward Definition & Key the palm Complications Limits range of motion and impairs quality of life Affects up to 7% of adults in the U.S. Post- treatment: P
Slide 6: Commercial Highlights for DC
Commercial Highlights for DC ~6,400 vials shipped 3Q15 in U.S. 14% year-over-year increase ~1.2 vials/patient First commercial sale in Japan in September 2015 Updated U.S. label including recurrence and retreatment data approved in May 2015 MULTICORD USS. label expansion approved in October 2014 Tre
Slide 7: XIAFLEX for Peyronie's Disease
XIAFLEX for Peyronie’s Disease First, Effective Non-Surgical Treatment Option Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable Definition & plaque, penile deformity and erectile dysfun
Slide 8: Commercial Highlights for PD
Commercial Highlights for PD ~7,500 vials shipped 3Q15 in U.S. 33% year-over-year growth ~4.5 vials/patient Continued commercial progress and growth with certified physicians and new patients As of 3Q15 there were 2,325 certified physicians and 11,600 cumulative patients treated Approval in Switzerl
Slide 9: XIAFLEX Pipeline Programs
XIAFLEX Pipeline Programs Future Revenue-Generating Opportunities ineaion | freinial [ines [rez [raed Adhesive Capsulitis Phase 2b to initiate shortl Cellulite Phase 2b to initiate shortly eee Phase 2 top-line results 1H16 Canii ipa Endo has license for further development Fibrotdst Lateral Thigh En
Slide 10: CCH for Adhesive Capsulitis
CCH for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Definition & Complications Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can Potential to be require anesthe
Slide 11: Phase 2b Study of CCH in Adhesive Capsulitis/FSS
Phase 2b Study of CCH in Adhesive Capsulitis/FSS Objective & Rationale 321 Patients Enrolled at 35 Sites in the U.S. and Australia Outcome Measures Source: Endo Intemational, ple Double-blind, placebo-controlled study evaluating safety and efficacy in Stage 2 (frozen stage) unilateral idiopathic fro
Slide 12: Phase 2b Study Results of CCH in Adhesive Capsulitis/FSS
Phase 2b Study Results of CCH in Adhesive Capsulitis/FSS Strong, similar drug effect for key measures including forward flexion, shoulder abduction, external and internal rotation across both Phase 2a and Phase 2b trials Similar CCH patient improvement in pain seen across both trials Increased and u
Slide 13: CCH for Cellulite
CCH for Cellulite Definition Significant Market Opportunity as First Nonsurgical Therapy Positive Top-line Results Reported from Phase 2a Study in3Q14 Source: Endo Intemational, ple Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Affec
Slide 14: CCH for Cellulite
CCH for Cellulite Positive Top-line Data from Phase 2a Study Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with treatme
Slide 15: CCH for Human Lipomas
CCH for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Definition Potential to be Only Approved Nonsurgical Therapy U.S, Market Opportunity Top-Line Data from Phase 2 Opt-In Study Expected in 1H16 Encapsulated deposits of benign fatty tumors; detected as bulges under the skin No FDA-appr
Slide 16: Positive Phase Clinical Trial Results
Positive Phase 2 Clinical Trial Results Open label, dose escalation Phase 2 trial: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of commercial dose) achieved best
Slide 17: CCH for Lipomas in Canines
CCH for Lipomas in Canines Key Complications Potential to be Only Approved Nonsurgical Therapy Chien-804 Trial Results Lipomas can seriously restrict motion in older dogs Surgery can be risky due to the use of general anesthesia - especially for older dogs 1.7M dogs affected in the U.S. annually Bas
Slide 18: CCH for Uterine Fibroids
CCH for Uterine Fibroids Endo Encouraged by Results Reported to Date Pain, decreased fertility, miscarriage, heavy menstrual bleeding and frequent urination Definition & Key Complications Potential to be Primary indication for Nonsurgical Therapy hysterectomy in U.S. (33% to Option more than 40%) ~2
Slide 19: CCH for Lateral Thigh Fat
CCH for Lateral Thigh Fat Definition & Complications Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise and are unable to restrict their caloric intake In some cases, cyroli
Slide 20: CCH for Plantar Fibromatosis
CCH for Plantar Fibromatosis Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, Peyronie’s disease and adhesive capsulitis Current treatments include orthothotics and anti-
Slide 21: Endo Partnership for Development and Commercialization of CCH
Endo Partnership for Development and Commercialization of CCH >$67.9M Received to Date Future Payments Due to BioSpecifics from Endo Endo Opt-In Rights Sublicense Income from Endo Partnerships $67.9M received in licensing, sublicensing, milestone, COGS, and royalty payments as of September 30, 2015
Slide 22: Corporate Highlights
Corporate Highlights » Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications = Strong IP portfolio Long-term patent protection for injectable collagenase: Dupuytren’s Contracture: XIAFLEX has Drug product composition patent until 2028 and Biologic Exclusiv
Slide 23: Consistently Profitable Annually
Consistently Profitable Annually Financial Highlights (unaudited) For the nine months ended 09/30/15 09/30/14 Cash and equivalents, and investments $32,824,471 $21,961,252 Income Statement Revenues $16,611,268 $9,396,976 Other income 65,056 53,189 Costs and expenses (6,062,469) (5,296,263) Provision
Slide 24: Anticipated Upcoming Pipeline Milestones
Anticipated Upcoming Pipeline ° Milestones Upcoming Pipeline Milestones wens Q Phase 2 placebo-controlled opt-in trial top-line results in 1H16 ati QO Refining development plan Adhesive O Initiate Phase 2b trial shortly Capsulitis Cellulite Q Initiate Phase 2b trial shortly Canine Leethien Q Endo ha
Slide 25: Innovators in the development & commercialization of injectable collagenase
Ae? Innovators in the development & commercialization of INJECTABLE COLLAGENASE pei as BioSpecifics November 2015
Biospecifics Technologies — Investor Presentation (November 2015) on 6ix